Skip to main content
< Back to news
Winners of the third edition of the ChemoStart Acceleration Programme (Photo: Insud Pharma).
 27.01.2020

Droplite and New Born Solutions, winners of the Chemostart Acceleration Programme

Droplite and New Born Solutions, with office at the Barcelona Science Park, have been selected to participate in the ChemoStart Programme, an initiative from the Insud Pharma pharmaceutic group, that looks for promoting innovation and disruptive projects that help improving health and well-being of people. Both startups, with VB Devices –also winner of this third edition- will get support to improve their health solutions in internationalization, marketing, scalability or business commercialization.

 

The ChemoStar accelerator, promoted by Insud Pharma and leaded by Leandro Sigman, has had 12 finalist empreneurs of big level that presented their projects on the Pitch Day, celebrated last 23rd of January.

In the coming months, Insud Pharma will give support to the three winning startups: Droplite, NewBorn Solutions and VB Devices. With their own resources and group of mentors, Insud Pharma will advise and prepare them for the Investor Day, that will organize with its investors network to get the necessary funding to keep promoting projects in the future.

Droplite presented their innovative diagnosis device in vitro, fast and intelligent, based in immunoassays, that gives quantitative results in ten minutes and with only a drop of blood needed. In this way, it can detect and monitor, in a quantitative way, different pathologic agents in human and animals, and has a clear application in veterinary, fertility or allergies. Nowadays, the diagnostic areal of immunoassays is still ruled by lab proves that are slow and expensive.

According to André Guedes, CEO and co-founder of Droplit, “this solution gives answer to the necessity of having faster and more efficient proves for clinics and hospitals, making easier the job of the doctor.”

New Born Solutions presented its Project called Neosonics, a medical device for the easy, fast and effective detections of potentially serious infections in superficial liquids, as childhood meningitis. According to their data, 30% of survivors suffer permanent sequels when the illness has not an early recognition.

Its recognition is complex due to the only method, by protocol, is the lumbar puncture. In this way, according to the CEO and founder Javier Jimenez’s explanation, “this illness can appear with only a fever and lactating babies are a risk population. With this pen of ultrasounds and membrane of one use only, it will be possible to recognise in only a few seconds through the child fontanelle, and will enable a 95% reduction of punctures.